Urinary peptidomics identifies potential biomarkers for major depressive disorder

Psychiatry Res. 2014 Jun 30;217(1-2):25-33. doi: 10.1016/j.psychres.2014.02.029. Epub 2014 Mar 12.

Abstract

Major depressive disorder (MDD) is a debilitating psychiatric illness with no available objective laboratory-based diagnostic test. In this study, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based peptidomics was applied to identify potential urinary diagnostic biomarkers for MDD. A training set of 42 first-episode drug-naive MDD patients and 28 age- and gender-matched healthy controls (HC) was used to develop a peptide diagnostic pattern. Then, the diagnostic efficacy of this pattern was assessed in an independent blinded test set consisting of 24 MDD patients and 13 age- and gender-matched HC. A combination of five potential biomarkers was identified, yielding a sensitivity of 91.7% and specificity of 84.6% in the test set. Moreover, the protein precursors of four of the five peptides were identified by tandem mass spectrometric analysis: serum albumin, apolipoprotein A-I, protein AMBP, and basement membrane-specific heparan sulfate proteoglycan core protein. Taken together, the peptide pattern may be valuable for establishing an objective laboratory-based diagnostic test for MDD.

Keywords: Depression; Diagnosis; Diagnostic; MDD; Peptide pattern; Urine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / urine
  • Case-Control Studies
  • Depressive Disorder, Major / diagnosis*
  • Depressive Disorder, Major / urine*
  • Female
  • Humans
  • Male
  • Peptides / urine*
  • Proteome / analysis
  • Proteomics*
  • Sensitivity and Specificity
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Substances

  • Biomarkers
  • Peptides
  • Proteome